Renz P, et al. - Using the National Cancer Database, researchers investigated outcomes in patients with metastatic rectal adenocarcinoma with primary tumor resection with and without pelvic radiotherapy. From 2004 to 2014, the National Cancer Database was consulted for patients receiving chemotherapy with stage IV rectal adenocarcinoma. In that group, 4051 patients were identified with primary tumor resection. Data reported that the median survival was 46.3 months vs 35.3 months in favor of addition of radiotherapy. In addition to primary tumor resection, pelvic radiotherapy might be of significant benefit to patients receiving chemotherapy with metastatic rectal adenocarcinoma.